선택지 정리됨
Neuroendocrine tumor (NET): 국가별 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨고형암최종 확인 2026.06
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
임상시험 검색어
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Iobenguane I 131 (Azedra); belzutifan (Welireg)[1]FDA-approvedIobenguane-scan positive status required for iobenguane I 131 (Azedra); no mutation biomarker stated for belzutifan PPGL FDA approval; Unresectable, locally advanced, or metastatic PPGL requiring systemic anticancer therapy for Azedra; locally advanced, unresectable, or metastatic PPGL for belzutifan. · Azedra requires iobenguane scan positivity and systemic anticancer therapy need; source label may not reflect manufacturing availability. Belzutifan source is an FDA approval notice and not a full local access/reimbursement determination. No claim is made for countries outside the United States. Confidence/conflicts: High for U.S. labeled/approved indications; Azedra current commercial availability remains a follow-up gap because label and access may diverge.
- Iobenguane I 131 (Azedra); belzutifan (Welireg)[1]FDA-approvedIobenguane-scan positive status required for iobenguane I 131 (Azedra); no mutation biomarker stated for belzutifan PPGL FDA approval; Unresectable, locally advanced, or metastatic PPGL requiring systemic anticancer therapy for Azedra; locally advanced, unresectable, or metastatic PPGL for belzutifan. · Azedra requires iobenguane scan positivity and systemic anticancer therapy need; source label may not reflect manufacturing availability. Belzutifan source is an FDA approval notice and not a full local access/reimbursement determination. No claim is made for countries outside the United States. Confidence/conflicts: High for U.S. labeled/approved indications; Azedra current commercial availability remains a follow-up gap because label and access may diverge.
European Union
- Lutetium (177Lu) oxodotreotide / lutetium Lu 177 dotatate (Lutathera); everolimus (Afinitor); sunitinib (Sutent or sunitinib products)[2]EMA authorisedSomatostatin receptor expression for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus indication; no mutation biomarker required by fetched EMA pages; Unresectable, metastatic, progressive, or treatment-refractory GEP-NET contexts as stated by EMA; pancreatic NET and non-functional GI/lung NET settings for everolimus; pancreatic NET for sunitinib. · EMA central authorization does not establish reimbursement or availability in Germany, France, or other EU member states. Lutathera requires somatostatin-receptor expression; everolimus and sunitinib indications are subtype-limited. Confidence/conflicts: High for EMA authorization text; member-state reimbursement remains a gap.
- Lutetium (177Lu) oxodotreotide / lutetium Lu 177 dotatate (Lutathera); everolimus (Afinitor); sunitinib (Sutent or sunitinib products)[2]EMA authorisedSomatostatin receptor expression for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus indication; no mutation biomarker required by fetched EMA pages; Unresectable, metastatic, progressive, or treatment-refractory GEP-NET contexts as stated by EMA; pancreatic NET and non-functional GI/lung NET settings for everolimus; pancreatic NET for sunitinib. · EMA central authorization does not establish reimbursement or availability in Germany, France, or other EU member states. Lutathera requires somatostatin-receptor expression; everolimus and sunitinib indications are subtype-limited. Confidence/conflicts: High for EMA authorization text; member-state reimbursement remains a gap.
United Kingdom
- Lutetium (177Lu) oxodotreotide (Lutathera); everolimus (Afinitor); sunitinib (Sutent); best supportive care comparator context[3]ApprovedSomatostatin receptor-positive status for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus as stated by NICE; no mutation biomarker required by fetched NICE recommendations; Unresectable or metastatic progressive GEP-NET; pancreatic NET progressive disease; non-functional GI or lung NET progressive disease, as specified in NICE recommendations. · NICE recommendations mainly apply to England and Wales NHS commissioning contexts and do not equal MHRA label review. Commercial-arrangement and patient-access-scheme conditions apply. Scotland, Northern Ireland, private access, and current local commissioning details need separate verification. Confidence/conflicts: High for NICE recommendations; devolved UK commissioning and current MHRA label specifics remain active gaps.
- Lutetium (177Lu) oxodotreotide (Lutathera); everolimus (Afinitor); sunitinib (Sutent); best supportive care comparator context[3]ApprovedSomatostatin receptor-positive status for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus as stated by NICE; no mutation biomarker required by fetched NICE recommendations; Unresectable or metastatic progressive GEP-NET; pancreatic NET progressive disease; non-functional GI or lung NET progressive disease, as specified in NICE recommendations. · NICE recommendations mainly apply to England and Wales NHS commissioning contexts and do not equal MHRA label review. Commercial-arrangement and patient-access-scheme conditions apply. Scotland, Northern Ireland, private access, and current local commissioning details need separate verification. Confidence/conflicts: High for NICE recommendations; devolved UK commissioning and current MHRA label specifics remain active gaps.
- Lutetium (177Lu) oxodotreotide (Lutathera); everolimus (Afinitor); sunitinib (Sutent); best supportive care comparator context[3]ApprovedSomatostatin receptor-positive status for lutetium (177Lu) oxodotreotide; non-functional status for GI/lung everolimus as stated by NICE; no mutation biomarker required by fetched NICE recommendations; Unresectable or metastatic progressive GEP-NET; pancreatic NET progressive disease; non-functional GI or lung NET progressive disease, as specified in NICE recommendations. · NICE recommendations mainly apply to England and Wales NHS commissioning contexts and do not equal MHRA label review. Commercial-arrangement and patient-access-scheme conditions apply. Scotland, Northern Ireland, private access, and current local commissioning details need separate verification. Confidence/conflicts: High for NICE recommendations; devolved UK commissioning and current MHRA label specifics remain active gaps.
출처
- U.S. Food and Drug Administration / Drugs@FDA — official drug label · official drug label
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- NICE — technology appraisal final appraisal document · technology appraisal final appraisal document
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.